Do analysts rate ADXS or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADXS or CURX more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Curanex Pharmaceuticals N/A -85.41% -82.11%

Do analysts prefer PYRGF or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend CURX or GRCE?

Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 157.51%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Grace Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, CURX or GRCE?

Grace Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A Grace Therapeutics N/A N/A -$7.79M -$0.48 N/A

Is CURX or GRCE more profitable?

Grace Therapeutics' return on equity of -14.45% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -85.41% -82.11% Grace Therapeutics N/A -14.45% -13.58%

Do analysts recommend INMB or CURX?

INmune Bio presently has a consensus target price of $8.00, indicating a potential upside of 492.59%. Given INmune Bio's stronger consensus rating and higher possible upside, research analysts clearly believe INmune Bio is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.17 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is INMB or CURX more profitable?

Curanex Pharmaceuticals' return on equity of -85.41% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Curanex Pharmaceuticals N/A -85.41% -82.11%

Do analysts rate GRDX or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRDX or CURX more profitable?

Entero Therapeutics' return on equity of -49.81% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Curanex Pharmaceuticals N/A -85.41% -82.11%

Curanex Pharmaceuticals (CURX) Competitors

$0.26 -0.01 (-3.28%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$0.27 +0.00 (+1.13%)

As of 06/24/2026 07:30 PM Eastern

Compare

CURX vs. ADXS, PYRGF, GRCE, INMB, and GRDX

Should you buy Curanex Pharmaceuticals stock or one of its competitors? MarketBeat compares Curanex Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Curanex Pharmaceuticals include Ayala Pharmaceuticals (ADXS), PyroGenesis Canada (PYRGF), Grace Therapeutics (GRCE), INmune Bio (INMB), and Entero Therapeutics (GRDX). These companies are all part of the "pharmaceutical products" industry.

How does Curanex Pharmaceuticals compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ayala Pharmaceuticals' return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

In the previous week, Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Curanex Pharmaceuticals	Neutral

Curanex Pharmaceuticals has lower revenue, but higher earnings than Ayala Pharmaceuticals. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Ayala Pharmaceuticals beats Curanex Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Curanex Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

In the previous week, PyroGenesis Canada had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 1 mentions for PyroGenesis Canada and 0 mentions for Curanex Pharmaceuticals. PyroGenesis Canada's average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Curanex Pharmaceuticals	Neutral

0.0% of PyroGenesis Canada shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curanex Pharmaceuticals has lower revenue, but higher earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.58	-$21.12M	-$0.04	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

Summary

PyroGenesis Canada beats Curanex Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Grace Therapeutics?

Curanex Pharmaceuticals (NASDAQ:CURX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Grace Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$0.48	N/A

Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 157.51%. Given Grace Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Grace Therapeutics is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Grace Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.1% of Grace Therapeutics shares are owned by institutional investors. 11.1% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Grace Therapeutics had 3 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 3 mentions for Grace Therapeutics and 0 mentions for Curanex Pharmaceuticals. Grace Therapeutics' average media sentiment score of 0.90 beat Curanex Pharmaceuticals' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Neutral
Grace Therapeutics	Positive

Grace Therapeutics' return on equity of -14.45% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
Grace Therapeutics	N/A	-14.45%	-13.58%

Summary

Grace Therapeutics beats Curanex Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to INmune Bio?

INmune Bio (NASDAQ:INMB) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

In the previous week, INmune Bio had 2 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 2 mentions for INmune Bio and 0 mentions for Curanex Pharmaceuticals. INmune Bio's average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
INmune Bio	Neutral
Curanex Pharmaceuticals	Neutral

12.7% of INmune Bio shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Curanex Pharmaceuticals' return on equity of -85.41% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

Curanex Pharmaceuticals has lower revenue, but higher earnings than INmune Bio. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	717.66	-$45.93M	-$1.67	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

INmune Bio presently has a consensus target price of $8.00, indicating a potential upside of 492.59%. Given INmune Bio's stronger consensus rating and higher possible upside, research analysts clearly believe INmune Bio is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

INmune Bio beats Curanex Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:GRDX) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Curanex Pharmaceuticals has lower revenue, but higher earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	734.83	-$6.39M	-$1.88	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A

12.3% of Entero Therapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Entero Therapeutics' average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Curanex Pharmaceuticals	Neutral

Entero Therapeutics' return on equity of -49.81% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Entero Therapeutics beats Curanex Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get Curanex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CURX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CURX vs. The Competition

Export

Metric	Curanex Pharmaceuticals	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$7.77M	$935.75M	$5.00B	$12.32B
Dividend Yield	N/A	4.84%	11.45%	5.88%
P/E Ratio	-0.98	1.44	22.00	23.95
Price / Sales	N/A	117.32	155.03	107.90
Price / Cash	N/A	20.06	39.06	53.76
Price / Book	0.66	7.78	15.93	6.41
Net Income	-$4.22M	-$4.18M	$115.37M	$337.14M
7 Day Performance	-5.36%	0.89%	-1.69%	-1.06%
1 Month Performance	-20.06%	1.95%	-2.46%	0.49%
1 Year Performance	N/A	46.36%	11.43%	28.43%

Curanex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CURX Curanex Pharmaceuticals	N/A	$0.27 -3.3%	N/A	N/A	$7.77M	N/A	N/A	N/A	Positive News Gap Down
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
PYRGF PyroGenesis Canada	N/A	$0.17 +2.3%	N/A	-55.5%	$35.28M	$9.14M	N/A	90
GRCE Grace Therapeutics	2.8271 of 5 stars	$2.22 flat	$6.00 +170.3%	-22.3%	$34.35M	N/A	N/A	N/A	Earnings Report
INMB INmune Bio	1.1348 of 5 stars	$1.30 +1.6%	$8.00 +515.4%	-79.6%	$34.03M	$50K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CURX) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. ADXS, PYRGF, GRCE, INMB, and GRDX

How does Curanex Pharmaceuticals compare to Ayala Pharmaceuticals?

Summary

How does Curanex Pharmaceuticals compare to PyroGenesis Canada?

Summary

How does Curanex Pharmaceuticals compare to Grace Therapeutics?

Summary

How does Curanex Pharmaceuticals compare to INmune Bio?

Summary

How does Curanex Pharmaceuticals compare to Entero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. ADXS, PYRGF, GRCE, INMB, and GRDX

How does Curanex Pharmaceuticals compare to Ayala Pharmaceuticals?

Do insiders and institutionals have more ownership in ADXS or CURX?

Is ADXS or CURX more profitable?

Does the media prefer ADXS or CURX?

Which has better valuation and earnings, ADXS or CURX?

Do analysts rate ADXS or CURX?

Summary

How does Curanex Pharmaceuticals compare to PyroGenesis Canada?

Is PYRGF or CURX more profitable?

Does the media prefer PYRGF or CURX?

Do institutionals and insiders hold more shares of PYRGF or CURX?

Do analysts prefer PYRGF or CURX?

Which has higher earnings & valuation, PYRGF or CURX?

Summary

How does Curanex Pharmaceuticals compare to Grace Therapeutics?

Which has better valuation & earnings, CURX or GRCE?

Do analysts recommend CURX or GRCE?

Do insiders & institutionals believe in CURX or GRCE?

Does the media refer more to CURX or GRCE?

Is CURX or GRCE more profitable?

Summary

How does Curanex Pharmaceuticals compare to INmune Bio?

Does the media refer more to INMB or CURX?

Do insiders and institutionals believe in INMB or CURX?

Is INMB or CURX more profitable?

Which has better earnings & valuation, INMB or CURX?

Do analysts recommend INMB or CURX?

Summary

How does Curanex Pharmaceuticals compare to Entero Therapeutics?

Which has higher valuation & earnings, GRDX or CURX?

Do institutionals and insiders hold more shares of GRDX or CURX?

Does the media prefer GRDX or CURX?

Is GRDX or CURX more profitable?

Do analysts rate GRDX or CURX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools